Metalert, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Metalert, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $687.0K | Apr 16, 2019 |
| FY2018 | Dec 31, 2017 | $538.4K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $703.6K | Apr 3, 2018 |
| FY2016 | Dec 31, 2015 | $449.3K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $138.3K | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | $150.0K | Apr 15, 2015 |
| FY2013 | Dec 31, 2012 | $367.1K | Apr 10, 2014 |
| FY2012 | Dec 31, 2011 | $663.8K | Apr 16, 2013 |
| FY2011 | Dec 31, 2010 | $425.1K | Mar 30, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $181.5K | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $248.3K | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $334.6K | May 24, 2024 |
| FY2022 | Dec 31, 2021 | $589.4K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.06M | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $1.50M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $687.0K | Mar 30, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $421.7K | Apr 3, 2018 |
| FY2017 | Dec 31, 2016 | $432.7K | Apr 3, 2018 |
| FY2016 | Dec 31, 2015 | $449.3K | Mar 31, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $116.6K | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $21.4K | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $144.8K | May 24, 2024 |
| FY2022 | Dec 31, 2021 | $255.3K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $460.3K | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $1.31M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $474.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $328.6K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $357.2K | Apr 3, 2018 |
| FY2016 | Dec 31, 2015 | $149.2K | Mar 31, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($828.3K) | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | ($1.19M) | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | ($1.50M) | May 24, 2024 |
| FY2022 | Dec 31, 2021 | ($1.20M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($368.4K) | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | ($586.3K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.76M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($1.27M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($1.22M) | Apr 3, 2018 |
| FY2016 | Dec 31, 2015 | ($1.28M) | Mar 31, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($557.5K) | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | ($876.9K) | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | ($1.37M) | May 24, 2024 |
| FY2022 | Dec 31, 2021 | ($904.5K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($627.2K) | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $187.3K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.02M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($1.03M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($922.7K) | Apr 3, 2018 |
| FY2016 | Dec 31, 2015 | ($1.29M) | Mar 31, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $18.9K | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $19.0K | May 24, 2024 |
| FY2022 | Dec 31, 2021 | $19.0K | Apr 17, 2023 |
| FY2022 | Dec 31, 2020 | $1.3K | Apr 17, 2023 |
| FY2020 | Dec 31, 2019 | $3.9K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $25.2K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $49.1K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $3.6K | Apr 3, 2018 |
| FY2012 | Dec 31, 2012 | $5.0K | Apr 16, 2013 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($438.6K) | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | ($417.2K) | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | ($507.0K) | May 24, 2024 |
| FY2022 | Dec 31, 2021 | ($497.7K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($556.6K) | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | ($140.9K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($416.3K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($632.2K) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($365.6K) | Apr 3, 2018 |
| FY2016 | Dec 31, 2015 | ($666.1K) | Mar 31, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $100.0K | Apr 17, 2023 |
| FY2019 | Dec 31, 2018 | $14.3K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $7.8K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $17.4K | Apr 3, 2018 |
| FY2016 | Dec 31, 2015 | $4.8K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $3.1K | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | ($1.1K) | Apr 15, 2015 |
| FY2013 | Dec 31, 2012 | $14.5K | Apr 10, 2014 |
| FY2012 | Dec 31, 2011 | $67.9K | Apr 16, 2013 |
| FY2011 | Dec 31, 2010 | $157.0K | Mar 30, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $534.1K | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $610.2K | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $163.8K | May 24, 2024 |
| FY2022 | Dec 31, 2021 | $400.3K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $298.2K | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $312.2K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $268.5K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $349.6K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $469.3K | Apr 3, 2018 |
| FY2016 | Dec 31, 2015 | $308.7K | Mar 31, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $4.98M | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $4.51M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $3.48M | May 24, 2024 |
| FY2022 | Dec 31, 2021 | $3.28M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $3.40M | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $3.91M | Mar 31, 2021 |
| FY2018 | Dec 31, 2018 | $3.72M | Apr 16, 2019 |
| FY2018 | Dec 31, 2017 | $2.56M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $1.95M | Apr 3, 2018 |
| FY2016 | Dec 31, 2015 | $1.49M | Mar 31, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($4.45M) | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | ($3.90M) | Apr 16, 2025 |
| FY2024 | Dec 31, 2022 | ($3.31M) | Apr 16, 2025 |
| FY2023 | Dec 31, 2021 | ($3.08M) | May 24, 2024 |
| FY2022 | Dec 31, 2020 | ($3.08M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2019 | ($3.60M) | Apr 12, 2022 |
| FY2020 | Dec 31, 2018 | ($3.45M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | ($2.21M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | ($1.48M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2015 | ($1.18M) | Apr 3, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($29.57M) | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | ($28.75M) | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | ($27.56M) | May 24, 2024 |
| FY2022 | Dec 31, 2021 | ($26.05M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($24.18M) | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | ($23.56M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($22.82M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($21.01M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($19.74M) | Apr 3, 2018 |
| FY2016 | Dec 31, 2015 | ($18.52M) | Mar 31, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $53.5K | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $68.4K | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $8.5K | May 24, 2024 |
| FY2022 | Dec 31, 2021 | $138.3K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $76.9K | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $125.2K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $69.9K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.5K | Apr 16, 2019 |
| FY2018 | Dec 31, 2016 | $95.4K | Apr 16, 2019 |
| FY2017 | Dec 31, 2015 | $7.9K | Apr 3, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $670.0K | Apr 3, 2018 |
| FY2017 | Dec 31, 2016 | $429.0K | Apr 3, 2018 |
| FY2016 | Dec 31, 2015 | $200.0K | Mar 31, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | 0 | May 24, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | 0 | May 24, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 34.75M | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | 32.45M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | 17.18M | May 24, 2024 |
| FY2022 | Dec 31, 2021 | 3.45M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 138.03M | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | 71.42M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 63.36M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 9.39M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | 510.37M | Apr 3, 2018 |
| FY2016 | Dec 31, 2015 | 355.43M | Mar 31, 2017 |